Research analysts who have asked questions during Inventiva earnings calls.
DL
Delphine Le Louet
Societe Generale
1 question for IVA
EW
Evan Wang
Guggenheim Securities
1 question for IVA
Also covers: ARCT, BOLD, IVVD +1 more
JL
Jean-Jacques Le Fur
Bryan, Garnier & Co
1 question for IVA
Jeroen Van den Bossche
KBC Securities
1 question for IVA
LC
Lucy-Emma Codrington-Bartlett
Jefferies Financial Group Inc.
1 question for IVA
Also covers: NBTX, ZLDPF
Recent press releases and 8-K filings for IVA.
Inventiva Provides Update on Lanifibranor Phase 3 Trial and Commercialization Plans
IVA
Product Launch
Management Change
New Projects/Investments
- Inventiva anticipates the readout of its fully enrolled phase three trial for its lead asset, Lanifibranor, in the second half of 2026, with a potential market launch in 2028.
- The company is fully capitalized, having raised $411 million in October 2024 and an additional $172 million in October 2025, with a cash balance projected to last until Q3 2027.
- Inventiva has significantly strengthened its management team and board, including the appointment of Andrew Obenshain as CEO and Mark Pruzanski as board chairman, bringing expertise relevant to the MASH market.
- Lanifibranor, an oral Pan-PPAR agonist for MASH, demonstrated positive results in a phase 2b study with an 18% effect size on fibrosis and 24% on fibrosis and MASH resolution, along with cardiometabolic benefits. The MASH market is projected to reach $15 billion by 2035.
Jan 15, 2026, 5:00 PM
Inventiva Provides Update on Lanifibranor Development and Commercialization Strategy
IVA
Product Launch
New Projects/Investments
Management Change
- Inventiva's lead asset, lanifibranor, an oral Pan-PPAR agonist for MASH, has a fully enrolled Phase III trial with results anticipated in the second half of 2026.
- The company is fully capitalized with a cash balance expected to last until Q3 2027, assuming positive data and a third tranche from the October 2024 PIPE.
- Inventiva anticipates a potential market launch for lanifibranor in 2028, with 2026 focused on strategic preparation for commercialization, including market research and building medical affairs presence.
- The MASH market is projected to grow to $15 billion by 2035, with the target F2/F3 patient population in the U.S. estimated at 375,000 patients, showing 20% growth since 2024.
- The management team has been strengthened with key hires, including a new CEO, board chairman, CMO, and head of regulatory, bringing significant experience in MASH and commercialization.
Jan 15, 2026, 5:00 PM
Inventiva Provides Update on Lanifibranor Phase 3 Trial and Commercialization Plans
IVA
New Projects/Investments
Management Change
Guidance Update
- Inventiva's lead asset, Lanifibranor, an oral therapy for MASH, has a fully enrolled Phase 3 trial with results anticipated in the second half of 2026.
- The company has secured substantial funding, including $411 million in October 2024 and $172 million in October (implied 2025), making it fully capitalized with a cash balance extending to Q3 2027.
- Inventiva has built an experienced management team with expertise in MASH and biotech commercialization, including a new CEO and board chairman.
- Following positive Phase 2b results, which showed an 18% effect size on fibrosis and 24% on fibrosis and MASH resolution, the company plans to start an outcomes trial in early 2027 and anticipates a potential market launch for Lanifibranor in 2028.
Jan 15, 2026, 5:00 PM
Inventiva Updates on Lanifibranor Phase 3 and Commercial Strategy
IVA
New Projects/Investments
Product Launch
Guidance Update
- Inventiva recently completed a successful fundraising to strengthen its balance sheet.
- The Phase 3 NATIVE 3 study for lanifibranor in MASH F2 and F3 patients was fully enrolled in April 2025 and is expected to have a data readout in the second half of 2026.
- The company is preparing for the market entry of lanifibranor, positioning it as an oral therapy for MASH F2 and F3 patients, highlighting its antifibrotic and antidiabetic effects.
- Inventiva plans to file the NDA for the U.S. first, followed by the MAA for the EMA, expeditiously after 2027, and is building its commercial and regulatory teams in 2026.
Dec 3, 2025, 3:15 PM
Inventiva Announces Full Exercise of Underwriters' Option, Bringing Offering Proceeds to $172.5M
IVA
- On November 17, 2025, Inventiva announced the full exercise of the underwriters' option to purchase 5,844,155 additional American Depositary Shares (ADSs).
- This exercise increased the total number of ADSs issued in the offering to 44,805,193.
- The full exercise of the option resulted in approximately $172.5 million in gross proceeds and an estimated $161.2 million in net proceeds for the company.
- The offering price for each ADS was $3.85.
- The additional ADSs are expected to be delivered on November 18, 2025.
Nov 17, 2025, 11:05 AM
Inventiva S.A. Reports Increased Net Loss in H1 2025 Amid Strategic Restructuring and Financing Activities
IVA
Earnings
Layoffs
New Projects/Investments
- Inventiva S.A. reported a net loss of €175.9 million for the first half of 2025, a significant increase from the €49.0 million net loss in the first half of 2024, primarily due to a €113.2 million net financial loss.
- The company completed patient enrollment in its NATiV3 Phase 3 clinical trial for lanifibranor on April 1, 2025, with topline results for Part 1 targeted for the second half of 2026.
- In February 2025, Inventiva S.A. implemented a Strategic Pipeline Prioritization Plan to focus exclusively on lanifibranor development, which included a workforce reduction of approximately 50%.
- Inventiva S.A. secured the €116 million second tranche of its structured financing on May 5, 2025, and received a $10 million milestone payment from CTTQ on July 7, 2025, contributing to €4.5 million in revenues for the first half of 2025.
- As of June 30, 2025, the company held €122.1 million in cash and cash equivalents.
Oct 14, 2025, 8:39 PM
Inventiva Provides Update on Lanifibranor Phase 3 Trial and Management Changes
IVA
CEO Change
Management Change
New Projects/Investments
- Inventiva (IVA) recently appointed Andrew Ovenshain as CEO and strengthened its management team, following a $400+ million PIPE raise approximately a year ago.
- The global Phase 3 NATIVE 3 trial for its MASH therapy, lanifibranor, was fully enrolled in April 2025, with top-line results anticipated in the second half of 2026 and a commercial launch targeted for 2028.
- Lanifibranor, a pan-PPAR agonist, showed an 18% improvement in fibrosis in six months in Phase 2b data and is positioned to address the significant unmet need in the MASH market, which is currently 10% diagnosed out of 18 million US patients.
Oct 8, 2025, 4:00 PM
Inventiva Appoints Andrew Obenshain as CEO
IVA
CEO Change
Management Change
Board Change
- Inventiva announced the appointment of Andrew Obenshain as its new Chief Executive Officer (CEO), effective October 1, 2025.
- Mr. Obenshain will also join the Company’s Board of Directors.
- He succeeds co-founder Frédéric Cren, who served as CEO for 13 years and is also stepping down from the Board of Directors.
- This leadership transition is a strategic decision to support Inventiva's next stage of growth, with a focus on preparing for potential commercialization in the United States for MASH and building a global footprint.
- Mr. Obenshain brings over 20 years of global leadership experience in drug development, regulatory strategy, and commercialization, including his previous role as CEO of bluebird bio.
Oct 1, 2025, 10:05 AM
Inventiva Appoints New Chief Executive Officer
IVA
CEO Change
Management Change
Hiring
- Inventiva announced the appointment of Andrew Obenshain as its new Chief Executive Officer, effective October 1, 2025.
- Mr. Obenshain succeeds co-founder Frédéric Cren, who served as CEO since the company's inception in 2012.
- This leadership transition is a strategic decision to support Inventiva's next stage of growth, with a particular focus on preparing for potential commercialization in the United States and expanding its global footprint.
- Andrew Obenshain brings over 20 years of global leadership experience in drug development, regulatory strategy, and commercialization, having previously been the CEO of bluebird bio.
Oct 1, 2025, 6:32 AM
Inventiva Reports H1 2025 Financial Results and Corporate Update
IVA
Earnings
Guidance Update
Layoffs
- Inventiva reported €4.5 million in revenues for the first half of 2025, a significant increase from the same period in 2024, and a net loss of €(175.9) million for the period ended June 30, 2025.
- As of June 30, 2025, the company held €122.1 million in cash and cash equivalents and €24.6 million in short-term deposits, with a cash runway currently planned until the end of the third quarter of 2026.
- The company completed enrollment for its pivotal Phase 3 NATiV3 clinical trial in April 2025, with topline results anticipated in the second half of 2026.
- Inventiva reinforced its financial position by receiving €115.6 million in gross proceeds from the second tranche of its structured financing in May 2025 and implemented a pipeline prioritization plan in February 2025, including a 50% workforce reduction, to focus exclusively on lanifibranor development.
Sep 29, 2025, 11:23 AM
Quarterly earnings call transcripts for Inventiva.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more